Caris Life Sciences Quarterly Income Statement
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Caris Life Sciences revenue and earnings
In the quarter ended Jun 30, 2026, Caris Life Sciences generated $263.7 million in revenue, up 45.4% from the same quarter a year earlier. Caris Life Sciences reported a net loss of $637,000, compared with a loss of $71.8 million a year earlier. Operating margin was 10.2%.
Diluted earnings per share came in at $0.00.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 263.71M | 216.17M | 292.89M | 216.83M | 181.40M | 120.92M | 129.91M | 101.62M | 100.05M |
| Revenue growth (YoY) | +45.38% | +78.78% | +125.44% | +113.38% | +81.31% | — | — | — | — |
| Research & Development | 32.36M | 31.32M | 31.84M | 21.62M | 25.05M | 23.07M | 27.11M | 27.64M | 24.79M |
| Selling, General & Admin | 120.31M | 104.75M | 100.66M | 93.24M | 106.63M | 91.95M | 80.64M | 77.61M | 79.78M |
| Operating Income | 26.93M | 5.28M | 88.41M | 32.64M | -17.99M | -57.95M | -37.05M | -60.84M | -67.01M |
| Interest Expense | 9.23M | 12.81M | 11.36M | 13.51M | 19.21M | 12.78M | 13.26M | 13.80M | 13.67M |
| Other Income (Expense) | -27.54M | -5.93M | -6.45M | -8.32M | -53.80M | -44.63M | 99.00K | -6.89M | 825.00K |
| Pretax Income | -614.00K | -644.00K | 81.96M | 24.32M | -71.79M | -102.58M | -36.95M | -67.73M | -66.19M |
| Income Tax | 23.00K | -134.00K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -637.00K | -510.00K | 81.96M | 24.32M | -71.79M | -102.58M | -36.95M | -67.73M | -66.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | 0.00 | 0.00 | 8.23 | 0.09 | -7.97 | -3.57 | — | -2.59 | -2.54 |
| EPS (Diluted) | 0.00 | 0.00 | 8.24 | 0.08 | -7.97 | -3.57 | — | -2.59 | -2.54 |
| Shares Outstanding (Basic) | 282.89M | 282.56M | — | 282.10M | 64.92M | 35.62M | — | 35.64M | 35.37M |
| Shares Outstanding (Diluted) | 282.89M | 282.56M | — | 297.21M | 64.92M | 35.62M | — | 35.64M | 35.37M |
| EBITDA | 33.43M | 10.35M | 92.70M | 37.54M | -11.59M | -50.91M | -27.98M | -50.34M | -55.41M |
| Operating Margin | 10.21% | 2.44% | 30.19% | 15.05% | -9.92% | -47.93% | -28.52% | -59.87% | -66.98% |
| Net Margin | -24.00% | -24.00% | 27.98% | 11.22% | -39.58% | -84.84% | -28.44% | -66.65% | -66.15% |
This table shows 9 quarterly periods of Caris Life Sciences's income statement, from Q2 2026 back to Q2 2024, across 16 line items including revenue, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow CAI's reporting calendar. What is a income statement?